PMS31 Cost-Effectiveness Analysis of Golimumab for the Treatment of Rheumatoid Arthritis

  • Desai R
  • Rao J
  • Biddle A
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVES: Rheumatoid arthritis (RA) affects~1.3 million Americans, accounting for 9 million physician visits and >250,000 hospitalizations annually. Drug therapy is costly but essential. This study evaluates the cost-effectiveness of golimumab, a recently approved TNF-+ inhibitor (TNF-I) compared with existing agents (infliximab, etanercept, adalimumab), when given in combination with methotrexate (MTX) from a third-party payer perspective. METHODS: A Markov model was constructed to follow a hypothetical cohort of 10,000 patients with active RA who received one of the four TNF-I and MTX across patient life-time. The primary effectiveness outcomes were the American College of Rheumatology (ACR)-20 response rates mapped to health assessment questionnaire-scores to derive qualityadjusted life-years (QALYs). ACR-20 rates were derived from a systematic review of efficacy trials. Long-term drug withdrawal rates were derived from observational studies. Data for drug, administration, monitoring, toxicity and RA-related direct costs were derived from the literature. Incremental costs (2011 US$) per QALY were compared between TNF-Is. One-way and probabilistic sensitivity analysis (PSA) techniques were employed to examine effects of various assumptions and parameter uncertainty. RESULTS: Golimumab+MTX generated the highest per-person QALYs (3.75 QALY), whereas infliximab+MTX strategy generated the least QALYs (3.57). Infliximab+MTX resulted in the least direct costs of $317,455 over the patient's life-time compared to etanercept+MTX ($324,855), adalimumab+MTX ($323,503) and golimumab+MTX ($324,159). The base-case incremental cost-effectiveness ratios (ICERs) foretanercept+MTX, adalimuamab+MTX, and golimumab+MTXcompared to infliximab+MTX were $69,211, $44,465 and $38,255/ QALY, respectively. Golimumab+MTX dominated etanercept+MTX, while the ICER for golimumab+MTX vs adalimumab+MTX was $16,729/QALY. In one-way sensitivity analyses, these results were robust to a range of assumptions except for dosing of infliximab and long-term withdrawal rates. In the PSA, the probability of golimumab being cost-effective at the commonly accepted $50,000/QALY threshold was 0.29. CONCLUSIONS: Golimumab appears to be a cost-effective treatment option for RA compared to existing TNF-Is.

Cite

CITATION STYLE

APA

Desai, R. J., Rao, J., & Biddle, A. K. (2012). PMS31 Cost-Effectiveness Analysis of Golimumab for the Treatment of Rheumatoid Arthritis. Value in Health, 15(4), A39. https://doi.org/10.1016/j.jval.2012.03.220

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free